BMY logo

BMYBristol-Myers Squibb Co.

$56.24
$0.89
(1.56%)
Today
Closed $56.24
$0.06
(0.11%)
After Hours
Updated: 07:54 PM EDT
EarningsJul 30
Mkt Cap$116.66B
Vol13.56M
News
all
press releases
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?
BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.
Zacks
News Placeholder
More News
News Placeholder
A Congress Member Sold Up To $65K In Bristol-Myers Squibb Stock: Here's What You Need To Know
read more...
Benzinga
News Placeholder
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.
Zacks
News Placeholder
Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
News Placeholder
The $100 Billion Oncology Opportunity Investors are Starting to Notice
Artificial intelligence continues to dominate healthcare headlines, but another transformative story is quietly unfolding across biotechnology: the race to develop more effective treatments for some of the deadliest forms of cancer. From precision oncology and targeted therapies to next-generation approaches designed to overcome treatment resistance, a new wave of innovation is emerging that could reshape cancer care over the next decade. $NTHI, $GSK, $NUVL, $PFE, $RHHBY, $BMY
24-7 Market News
News Placeholder
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
Zacks
News Placeholder
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock?
Argenx (ARGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
News Placeholder
Mariska Hargitay Partners with Bristol Myers Squibb for Investigating Myeloma Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
Bristol Myers Squibb (NYSE: BMY) today announced the launch of Investigating Myeloma, a multiple myeloma awareness campaign, in partnership with award-winning actor, director, producer and advocate Mariska Hargitay. This campaign spotlights the importance of ongoing scientific investigation in...
Business Wire
News Placeholder
Bristol Myers Squibb (BMY) Gains As Market Dips: What You Should Know
In the latest trading session, Bristol Myers Squibb (BMY) closed at $57.27, marking a +1.18% move from the previous day.
Zacks
News Placeholder
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Zacks
<
1
2
...
>

Advertisement|Remove ads.